Single CRISPR-Cas9 Infusion Shows Lasting Reductions in Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human Phase 1 clinical trial conducted by the Cleveland Clinic has yielded remarkable preliminary results, demonstrating that a single infusion of a CRISPR-Cas9 gene-editing therapy can produce profound and…